| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | KU-0063794 | CTRPv2 | pan-cancer | AAC | -0.012 | 0.7 |
| mRNA | BRD1835 | CTRPv2 | pan-cancer | AAC | -0.013 | 0.7 |
| mRNA | navitoclax:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.011 | 0.7 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | 0.015 | 0.7 |
| mRNA | Irinotecan | CCLE | pan-cancer | AAC | -0.018 | 0.7 |
| mRNA | NVP-BEZ235 | CTRPv2 | pan-cancer | AAC | 0.014 | 0.7 |
| mRNA | CAY10594 | CTRPv2 | pan-cancer | AAC | 0.012 | 0.7 |
| mRNA | BRD-K44224150 | CTRPv2 | pan-cancer | AAC | -0.024 | 0.7 |
| mRNA | Bortezomib | FIMM | pan-cancer | AAC | 0.053 | 0.7 |
| mRNA | betulinic acid | CTRPv2 | pan-cancer | AAC | -0.012 | 0.7 |